Try it
OBG · Gynaecological oncology: eligibility for ablative treatment
Sample itemUnder a screen-and-treat programme, VIA is positive in a 38-year-old woman. Which finding makes her eligible for cryotherapy or thermal ablation?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. The lesion is wholly visible, within the transformation zone, with no extension into the endocervical canal, covering less than 75 percent of the cervix
Ablative treatments such as cryotherapy and thermal (cold) coagulation destroy tissue to a limited depth, so they are used for lesions that are fully visible, confined to the ectocervix and not too large. Lesions extending into the canal, large lesions or suspected cancer need excision (LEEP) or referral. WHO recommends screen-and-treat for settings where follow-up is difficult.
Option by option
A. Lesion extending deep into the canal
Canal extension cannot be adequately treated by ablation.
B. Lesion extending onto the vaginal wall and parametrium
Extension to the vagina or parametrium suggests more advanced disease.
C. The lesion is wholly visible, within the transformation zone, with no extension into the endocervical canal, covering less than 75 percent of the cervix (correct)
Correct. Small, wholly visible ectocervical lesions suit ablation.
D. Suspected invasive cancer
Suspected invasive cancer needs biopsy and referral.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More OBG questions
- Antenatal careA woman's last menstrual period began on 10 January 2026. Using Naegele's rule, what is…
- Obstetric drugsCarboprost (15-methyl PGF2α) is contraindicated in which condition?
- Hypertensive disorders of pregnancyA primigravida at 34 weeks has a blood pressure of 150/100 mmHg on two occasions and 2+…
- Obstetric immunologyAn Rh-negative mother delivers an Rh-positive baby. When should anti-D immunoglobulin be…